TeleVox, a high-tech engagement communications company that provides automated voice, email, text and web solutions that activate positive patient behaviors through the delivery of a human touch, recently released a study combining consumer and healthcare provider opinion entitled “Healthcare Change: The Time is Now” . The report, which addresses the healthcare industry’s essential shift away from primarily treating illness to keeping people healthy, reveals that the majority of healthcare practices across the country aren’t prepared to meet the demand of the 46.6 million Medicare beneficiaries who are now eligible for wellness visits.
Study Finds Few Baby Boomers Receiving, Few Healthcare Practices Prepared to Offer Medicare Wellness Visits
Perhaps among the most confusing of nutrition and wellness decisions that the average consumer must make is whether to take dietary supplements. The available information is deeply contradictory; while some supplements — like folic acid for pregnant women and vitamin D for babies — are considered nearly essential in medical care, research suggests that other supplements may be ineffective or even deleterious to health. A recent research summary published in The Medical Letter On Drugs and Therapeutics may help consumers and practitioners to wade through the conflicting information on supplements, as many supplements have both risks and benefits associated with their use .
New research published in this month’s Archives of Internal Medicine has caused quite a stir amongst vitamin- and mineral-popping Americans . Researchers report that over the course of a decades-long study, older women who regularly took vitamin and mineral supplements were more likely to die than those who did not.
This news may surprise those who look to vitamin and mineral supplements as a mechanism for maintaining — and even improving — health. However, while it would be easy to sensationalize the research findings, the reality is that there are many limitations that prevent drawing meaningful conclusions — ones that could be used to inform behavior — from the study.
Biomarker Bulletin is an occasionally recurring update of news focused on biomarkers aggregated at BiomarkerCommons.org. Biomarkers are physical, functional or biochemical indicators of normal physiological or disease processes. The individualization of disease management — personalized medicine — is dependent on developing biomarkers that promote specific clinical domains, including early detection, risk, diagnosis, prognosis and predicted response to therapy.
- Recent Advances in Biomarker Discovery for Parkinson’s disease, a Satellite Symposium at the Society for Neuroscience Annual Meeting
A satellite symposium, Recent Advances in Biomarker Discovery for Parkinson’s Disease, is being sponsored by Covance on November 13th, 2011 at the Society for Neuroscience Annual Meeting in Washington, D.C.
- NYAS Symposium: Biomarkers and Brain Imaging of Presymptomatic Alzheimer’s Disease
The New York Academy of Sciences (NYAS) will be holding an afternoon event in January 2012 that focuses on biomarkers and brain imaging of presymptomatic Alzheimer’s disease.
- NIH to Support Clinical Trial Implementation or Biomarker Clinical Evaluation Studies
Earlier this month, the National Institutes of Health announced that the National Institute of Dental and Craniofacial Research (NIDCR) Institute will support mission-relevant investigator-initiated Phase I, II, III or IV clinical trial cooperative agreement applications or biomarker evaluation studies that require prospective collection of clinical outcomes and clinical specimens.
- NIH to Fund Studies that Adapt Adult Biomarkers to Children
The National Institutes of Health announced Thursday that the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) will support studies that propose adapting adult biomarkers to children.
- CLC bio to Develop Bioinformatics Tools for Prostate Cancer Biomarker Project
CLC bio is participating in a $4 million Danish collaboration focused on the identification and validation of biomarkers of prostate cancer risk and aggressiveness.